Rana McKay, MD, genitourinary oncologist at UC San Diego, joins the show to recap the clinically relevant research presented at the ASCO GU meeting. She begins with a breakdown of the ARASENS, PROpel, and MAGNITUDE trials for prostate cancer; moves to TROPHY-U-01, EV-103, and ATLANTIS trials for urothelial cancer; hits on KEYNOTE-564 for kidney cancer; and names a few other studies along the way that could move the needle in genitourinary cancers in the near future. *Plus – a surprise guest joins the show unannounced. You’ll have to listen to find out who it is!
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
